This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novus And Verenium Introduce The Newest Addition To Novus's Enzyme Solutions Portfolio: CIBENZA® PHYTAVERSE™

ST. LOUIS and SAN DIEGO, July 26, 2013  /PRNewswire/ -- Novus International, Inc. and Verenium Corporation (Nasdaq: VRNM) today announced the name of their new phytase enzyme product, CIBENZA ® PHYTAVERSE .  This new innovative phytase is specifically designed to unlock more of the hidden nutritional value in phytate for improved animal growth and well-being. 


The two companies, which entered into a strategic partnership in 2011, designed CIBENZA ® PHYTAVERSE to have specific performance characteristics that offer significant advantages over current phytase products.  These performance characteristics include:
  • High in vivo activity under gastric conditions for sustained performance
  • Improved activity at low substrate concentrations to maximize phytate hydrolysis
  • High gastric stability for activity throughout the upper gastrointestinal tract
  • High intrinsic thermotolerance and pelleting stability
  • Improved bioavailability due to the elimination of the need for thermo protective coatings

"We're excited to bring this new enzyme solution to the market," said Gary Hayen, Global Director Fermentation Products at Novus.  "The partnership with Verenium is allowing us to offer our customers the synergy of cutting-edge enzyme technology and nutrition solutions knowledge which makes CIBENZA ® PHYTAVERSE a valuable asset for today's feed industry."

Animal trial results have demonstrated the superior performance characteristics that CIBENZA ® PHYTAVERSE provides, based on standard metrics such as weight gain, feed conversion ratios and phosphorus mineralization (tibia ash) versus other available phytase products.  These results indicate that inclusion of CIBENZA ® PHYTAVERSE in monogastric diets can provide improved nutrition and economics to the animal feed industry.

"By combining Novus's animal nutrition expertise and extensive industry knowledge with over 15 years of experience in developing high-performance phytase products at Verenium, together we've been able to create a next-generation phytase that exhibits superior performance characteristics over those marketed today," said David Weiner, Vice President of R&D Strategy and Partnerships at Verenium. "These important characteristics allow the animal to more efficiently utilize the phosphorus and other nutrients necessary for improved animal health and nutrition, and can provide producers an increased return on investment."

Novus and Verenium expect to launch this product in certain geographical regions beginning in 2013.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,057.93 +7.18 0.04%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,826.9350 +16.1470 0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs